Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Onkaido Therapeutics

Request full access

About Onkaido Therapeutics

Cambridge, United StatesFounded 2013Biotechnology

About Onkaido Therapeutics

Onkaido Therapeutics was established in January 2014 as a strategic venture by Moderna Therapeutics, with an initial capital commitment of $20 million. This formation represented a focused effort by Moderna to create a standalone entity dedicated exclusively to accelerating the development of messenger RNA (mRNA) based treatments for oncology. The company was headquartered in Cambridge, Massachusetts, a major hub for the biotechnology industry.

The leadership at inception included Dr. Stephen Hoge as the founding Chief Executive Officer, a role he took on in addition to his position as senior vice president at Moderna. Dr. Hoge's background includes being a partner at McKinsey & Company, where he advised leading biotech and pharmaceutical companies, and his experience was instrumental in founding Moderna's internal oncology efforts. Peter F. Smith, Ph.D., served as the founding Chief Scientific Officer, bringing 30 years of pharmaceutical leadership from companies like Millennium Pharmaceuticals, Merck, and SmithKline. His experience included contributions to the development of major drugs such as Velcade.

Onkaido's core business was to leverage Moderna's mRNA Therapeutics™ platform to address previously undruggable cancer targets. The technology is designed to use mRNA to prompt the body's own cells to produce therapeutic proteins or antibodies internally, a method intended to work with the body's natural processes. This approach was aimed at creating a new modality for cancer treatment, potentially offering a superior alternative to existing drug options. The company's initial pipeline consisted of 15 pre-clinical drug candidates focusing on areas like apoptosis, central regulatory nodes, and immunotherapy. By operating as a separate unit, Onkaido was structured to intensely focus on the specific challenges and opportunities in oncology drug development.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1
Open positions
None listed
Dealroom signal
21.3/100
Sector
Hard Tech
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Jan 2014 $20M $80M Moderna Therapeutics —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Onkaido Therapeutics website traffic

Latest recorded traffic for Onkaido Therapeutics is 0 monthly website visits. Onkaido Therapeutics's team grew 0% over the past year.

Latest monthly visits0 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Onkaido Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Onkaido Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Moderna Therapeutics
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Onkaido Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Onkaido Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.